Status:

UNKNOWN

Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma

Lead Sponsor:

Cancer Research UK

Conditions:

Lymphoma

Eligibility:

All Genders

16-65 years

Phase:

PHASE2

Brief Summary

RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. Also, mo...

Detailed Description

OBJECTIVES: * To document the toxicity, feasibility, and survival after reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation from a matched sibling donor in p...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Confirmed diagnosis of Hodgkin lymphoma, meeting all of the following criteria:
  • Achieved partial or complete remission (using standard criteria) after salvage chemotherapy
  • Relapsed after first remission with residual fludeoxyglucose F 18-avid lesions
  • Available HLA-matched sibling donor
  • PATIENT CHARACTERISTICS:
  • WHO performance status 0-1
  • Creatinine clearance ≥ 50 mL/min (measured by EDTA clearance or 24-hour urine collection)
  • Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • Alkaline phosphatase ≤ 2 times ULN
  • LVEF ≥ 40%
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 2 months (or 3 months for women) after completion of study therapy
  • No other malignancy within the past 5 years except for nonmelanoma skin tumors or stage 0 (in situ) cervical carcinoma
  • No HIV positivity
  • No symptomatic respiratory compromise
  • No concurrent serious medical condition that would preclude transplantation
  • PRIOR CONCURRENT THERAPY:
  • See Disease Characteristics
  • No prior high-dose therapy or allograft

Exclusion

    Key Trial Info

    Start Date :

    July 1 2009

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    Estimated Enrollment :

    49 Patients enrolled

    Trial Details

    Trial ID

    NCT00907036

    Start Date

    July 1 2009

    Last Update

    August 2 2013

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

    Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma | DecenTrialz